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Abstract: Migraine and migraine variants are common, chronic and incapacitating neurovascular 
disorders with a high impact on health resources. There is an extensive evidence base provided 
by double-blind, placebo-controlled trials showing that topiramate is a safe, effective and well 
tolerated drug in the management of migraine and its variants, being especially promising in 
the management of migraine-vertigo syndrome. Models both in the US and the UK have also 
shown that it offers a cost benefit when direct and indirect costs are evaluated, by reducing work 
loss, improving quality of life and reducing the use of increasingly scarce health resources.
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Migraine is a chronic neurological disorder characterized by a throbbing cranial 
pain that typically lasts from 4 to 72 hours. It is a common, chronic, incapacitating 
neurovascular disorder, characterized by recurrent attacks of severe headache, and 
associated autonomic symptoms, eg, nausea, sensitivity to light and noise, and, in 
some patients, an aura involving neurologic symptoms.
Clinical manifestations
Migraine can be divided into two major subtypes:
Migraine without aura (MOA) is a clinical syndrome characterized by headache with 
specific features and associated symptoms.
Migraine with aura (MA), previously called classic or classical migraine, ophthalmic, 
hemiparesthetic, hemiplegic or aphasic migraine or complicated migraine, is primarily 
characterized by the focal neurological symptoms that usually precede or sometimes 
accompany the headache.
A combination of features is required for the diagnosis, but not all features are 
present in every attack or in every patient.
General comments
MOA is the commonest subtype of migraine. It has a higher average attack frequency 
and is usually more disabling than MA.
In approximately 15% of patients, migraine attacks are usually preceded or 
accompanied by transient focal neurologic symptoms, which are usually visual; such 
patients have MA.Therapeutics and Clinical Risk Management 2009:5 662
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In a recent large, population-based study, 64% of patients 
with migraine had only MOA, 18% had only MA, and 13% 
had both types of migraine (the remaining 5% had aura 
without headache).
Thus, up to 31% of patients with migraine have aura on 
some occasions, but clinicians who rely on the presence of 
aura for the diagnosis of migraine will miss many cases.
MOA often has a strict menstrual relationship. In contrast 
to the first edition of The International Classification of 
Headache Disorders, the second edition gives criteria for 
pure menstrual migraine and menstrual-related migraine.1
Very frequent migraine attacks are now distinguished as 
chronic migraine (CM) provided that there is no medication 
overuse. MOA is the disease most prone to accelerate 
with frequent use of symptomatic medication, resulting 
in a new headache which is termed medication-overuse 
headache (MOH).
MA
The aura is the complex of neurological symptoms that 
occurs just before or at the onset of migraine headache. Some 
patients also experience a premonitory phase, occurring hours 
to a day or two before a migraine attack. Premonitory and 
resolution symptoms include hyperactivity, hypoactivity, 
depression, craving for particular foods, repetitive yawning 
and other less typical symptoms reported by some patients. 
They include various combinations of: fatigue, difficulty in 
concentrating, neck stiffness, sensitivity to light or sound, 
nausea, blurred vision, yawning and pallor.
The terms prodrome and warning symptoms are best avoided 
because they are often mistakenly used to include aura.
Most migraine auras are associated with headache, 
fulfilling the criteria for MOA. Migraine aura is sometimes 
associated with a headache that does not fulfill the criteria for 
MOA and, in other cases, migraine aura may occur without 
headache. These two subforms are also now distinguished 
on the second classification.1
Aura with similar features has also been described 
in association with other well-defined headache types, 
including cluster headache; the relationships between aura 
and headache are not fully understood.
Epidemiologic data and life impact, 
and risk of progression caused  
by migraine
In the US and Western Europe, the 1-year prevalence of 
migraine is 11% of the adult population overall: 6% among men 
and 15% to 18% among women. The disabilities associated 
with migraine can be severe; migraine imposes considerable 
burdens on the sufferer and on society as well.2–6
We find it useful to assess the severity and effects of 
migraine by asking about days lost at work or school as a 
result of migraine, as well as in performing household work 
or chores, or in family, social, and leisure activities.7,8
Although attacks of migraine may start at any age, the 
incidence peaks in early to mid-adolescence.
Incidence of migraine
Despite the abundance of studies on the prevalence of 
migraine, studies on the incidence of migraine are relatively 
few. Several reports mentioned the findings of four studies 
that assessed the incidence of migraine.7–15 The variation 
in the results of these studies are not surprising given the 
differences in the study populations (eg, age, geographic 
area), as well as in the research methods employed.
Lipton et al used the reported age of migraine onset in a 
prevalence survey to indirectly estimate migraine incidence.7,8 
Because the study enrolled subjects aged 12 to 29 years, it did 
not account for migraine that begins after age 29 years and 
for short-duration migraine that fully remits. The study found 
that the incidence of MA reached a peak between ages 12 
and 13 years in females (14.1 per 1000 person-years), while 
MOA peaked between ages 14 and 17 years (18.9 per 1000 
person-years). In males, the incidence of MA peaked several 
years earlier (at 5 years of age; 6.6 per 1000 person-years). 
The earlier age of onset helps to explain why boys have a 
higher prevalence of migraine than girls. The peak for MOA 
in boys was 10 per 1000 person-years between ages 10 and 
11 years. New cases of migraine were uncommon among 
men in their twenties. The Lipton et al studies supports the 
concept that migraine begins earlier in males than in females 
and that MOA begins earlier than MA.
Another study, by Breslau et al,3 assessed the incidence 
of migraine in a random sample of young adults (aged 21 to 
30 years). The authors found that the incidence of migraine 
was 5.0 per 1000 person-years in men and 22.0 per 1000 
person-years in women, a lower incidence than that found by 
Stewart et al, whose study included younger subjects.
Stang et al used a linked medical records system to 
estimate the incidence of migraine.11–13 Because many 
migraine sufferers do not consult with doctors or do not 
receive a medical diagnosis of migraine, one would expect 
this method to underestimate incidence. In this study, the 
average annual incidence rate for the country was 3.4 per 
1000 person-years (2.9 per 1000 in women and 1.4 per 
1000 in men). Among women, the incidence rates were Therapeutics and Clinical Risk Management 2009:5 663
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lower at the extremes of age and higher among women 
aged 10 to 49 years, with a striking peak in women aged 
20 to 29 years.
A Danish study by Lyngberg et al showed that the annual 
incidence of migraine in people aged 25 to 64 years was 
8 per 1000 person-years (15 per 1000 in males and 3 per 
1000 in females).14 In 2001, the incidence of migraine peaked 
in women aged between 37 and 44 years at a rate of 20 per 
1000 person-years.
Prevalence of migraine
The prevalence of migraine has been extensively reviewed 
exhaustively by several authors.7–15
Prevalence by age and gender
Migraine is more common in boys than in girls before 
puberty. As adolescence approaches, the incidence and 
prevalence of migraine increase more rapidly in girls than in 
boys. In women, prevalence increases throughout childhood 
and early adult life until approximately age 40 years, after 
which it declines. Overall, the prevalence of migraine is 
highest from ages 25 to 55 years for men and women, the 
peak years of economic productivity, which, at least in part, 
explains the substantial influence of migraine on lost work 
time. Other studies found higher rates of prevalence. For adult 
populations, the estimates of migraine prevalence range from 
3.3% to 21.9% for women and 0.7% to 16.1% for men.
Data on the overall prevalence of migraine and prevalence 
by geographic location and gender were presented in the US 
during 1989. The American Migraine Study I collected 
information from 15,000 households representative of 
the US population.7,9 The American Migraine Study II, 
which used virtually identical methodology, was conducted 
10 years later. In these two very large studies, the prevalence 
of migraine was approximately 18% in women and 6% 
in men.8,9
A recent survey by the World Health Organization 
(WHO) rates severe migraine, along with quadriplegia, 
psychosis, and dementia, as one of the most disabling chronic 
disorders.2,5 This ranking suggests that in the judgment of the 
WHO, a day with severe migraine is as disabling as a day 
with quadriplegia. For this reason migraine is a common 
disabling primary headache disorder and epidemiological 
studies have documented its high prevalence and high 
socio-economic and personal impacts. It is now ranked by 
the World Health Organization as number 19 among all 
diseases in the general population as world-wide benign 
disease causing disability.
Burdens of migraine
Migraine is a disabling disorder that affects individuals, their 
families, and society.
Here we review the burden of migraine from economic 
and quality-of-life perspectives.5,9,13
Socioeconomic costs of migraine
For fatal illness, measures of mortality are used to assess 
reductions in quantity of life. For nonfatal illness, direct and 
indirect costs are measured.
Migraine, a public health problem of enormous scope, 
affects both the individual sufferer and on society. The 
American Migraine Study II estimated that 28 million people 
in the US have severe migraine headaches. Nearly 1 in 4 US 
households includes a person with migraine. Twenty-five 
per cent of women in the US with migraine have 4 or more 
severe attacks per month; 35% experience 1 to 4 severe 
attacks per month, while 38% experience 1 (or less than 1) 
severe attack per month.
A similar frequency pattern was observed for men in 
Argentina8–14 (for all conditions). Costs to society were 
estimated to be US$3.2 billion in 1999, and headache accounts 
for about one-third of over-the-counter (OTC) prescriptions. 
Stewart et al estimated that lost productivity due to headache 
(not just migraine) accounts for US$18 billion per year.7–9
Health-related quality of life (HRQoL) and disability 
measures quantify the burden of migraine. Migraine episodes 
not only impair an individual’s ability to function during 
an episode, but can also reduce the quality of life between 
episodes. The quality of life reflects an individual’s assess-
ment of general well-being and position in life within the 
context of culture, value systems, goals, and concerns. 
HRQoL is a subset that encompasses an individual’s state 
of health, functional status (both physical and mental), and 
overall well-being.9
Approximately one-half of migraine sufferers are 
severely disabled or needed bed rest during a migraine 
episode. Similarly, a Canadian population survey found that 
one-half of migraine sufferers discontinued normal activities 
during episodes of migraine and nearly one-third required bed 
rest. More than 70% of the migraine sufferers in this survey 
experienced impairments in interpersonal relationships.8,9
Migraine as a progressive disease
Recent evidence suggests that a subgroup of migraine 
sufferers may have a clinically progressive disorder5,16–18 in 
which migraine episodes increase in frequency over time 
until the individual is in nearly constant pain. Thus, the term Therapeutics and Clinical Risk Management 2009:5 664
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CM is characterized by the occurrence of headache on 15 or 
more days per month.
Another clue about progression comes from the finding by 
Welch et al that iron deposition occurs in the periaqueductal 
gray (PAG) area in subjects with chronic headaches.19
The PAG area is related to the descending analgesic 
network and is important in controlling pain and providing 
endogenous analgesia. It is closely related to the trigeminal 
nucleus. In this study by Welch et al,5,9,19 the iron levels were 
higher in migraine sufferers than in control subjects.
The authors propose that free-radical cell damage may 
lead to iron deposition, which reflects progressive neuronal 
damage related to recurrent migraine attacks. Perhaps 
repetitive central sensitization of the trigeminal neurons 
correlates with iron deposition in the PAG area and, therefore, 
frequently recurring migraine episodes may predispose a 
person-to-disease progression.5,9,20
Evidence of migraine progression also comes from a 
recent neuroimaging study. Kruit et al21 used a cross-sectional 
design to study Dutch adults aged 30 to 60 years. They 
showed that male subjects who experienced MA were at an 
increased risk of posterior circulation infarct. Additionally, 
women with MOA or MA were at a higher risk for deep 
white-matter lesions, compared with controls.
The white-matter lesions increased with episode frequency, 
possibly demonstrating progression of the disease.22
In a longitudinal epidemiologic study, Scher et al,15 
showed that over the course of 1 year, 3% of individuals 
with episodic headache (headache frequency from 2 to 
104 days per year) progressed to chronic daily headache 
(CDH), episode frequency 180 days per year.5,15,17
The authors concluded that the incidence of CDH in 
subjects with episodic headache is 3% per year. In a second 
study, Katsarava et al23 followed 532 consecutive patients with 
episodic migraine (15 days per month) for 1 year. Sixty-four 
patients (14%) developed chronic daily headache.5,15,19
Based on recent data, migraine is now understood not just 
as an episodic disorder, but as a chronic-episodic, and at times a 
chronic-progressive disorder. Ongoing research and emerging 
therapeutic strategies should take into account this change 
in the conceptual model of migraine. Preventing disease 
progression in migraine should be added to the existing goals 
of relieving pain and restoring a patient’s ability to function.
Transformed migraine  
(TM) and CDH9,16–18
Regular use of almost any migraine medication can lead to 
increasingly frequent headaches. The headaches can occur 
daily and are related to rebound withdrawal from frequent 
use of the antimigraine medication. Patients experiencing this 
phenomenon are said to have TM and often experience episodic 
migraine attacks superimposed on their daily headache. The 
combination OTC analgesics, combination prescription analge-
sics, narcotic-containing analgesics, and ergotamine-containing 
medications are especially prone to promote the development of 
CDH. Caffeine alone can cause a similar clinical picture. Expe-
rience with the triptans is limited; sumatriptan has been reported 
to cause rebound-withdrawal headaches. Dihydroengotamine 
rarely, if ever, leads to rebound headaches.
When patients are experiencing CDH due to rebound 
withdrawal, they do not usually respond to other acute or 
any preventive medications. Attempts to discontinue the 
medication that causes rebound withdrawal result in increased 
headache. Therefore, preventing the development of TM 
and CDH is preferable. The medications that are especially 
prone to cause TM are acceptable for occasional use, ie, 
the patient has 2 or fewer headaches per month. However, 
if the patient experiences migraine more frequently, use 
of single-ingredient, OTC or prescription medications or 
several medications on a rotating basis is recommended; the 
patient should be instructed to not use any single medication, 
including triptans, more than 2 days per week.
If the clinical history indicates that trigger or lifestyle 
issues (eg, poor sleep habits, considerable stress issues, poor 
nutrition) are a major issue for the patient, a short period of 
trying to correct these problems without instituting prophylactic 
medication may be reasonable, but undue delay may result in 
furthering the patient’s already considerable disability.
Comorbidities should be considered when choosing a 
prophylactic agent in all the patients. Obesity, epilepsy, 
asthma, depression, and sleep disturbances are relatively 
common problems and may influence which agent is chosen. 
There is no literature addressing the issue of medication 
discontinuation. Tailoring this to the patient’s individual 
needs is likely the best policy.
Preventive therapy: goals commonly 
accepted indications for migraine 
prophylaxis5,24–33
The indications for migraine prophylaxis include headache 
frequency (more than three per month) the duration and others 
factors presented in Table 1.
Medication use
Consensus-based principles of care will enhance the success 
of preventive treatment. Non-pharmacologic therapies Therapeutics and Clinical Risk Management 2009:5 665
Prophylatic treatment of migraine with topiramate Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
must be considered and take patient preference into 
consideration.
Take coexisting conditions into account, as some 
(comorbid/coexisting) conditions are more common in people 
with migraine: stroke, myocardial infarction, Raynaud’s 
phenomenon, epilepsy, affective and anxiety disorders. 
These conditions present both treatment opportunities and 
limitations:
A. Select a drug that will treat the coexistent condition and 
migraine, if possible.
B.  Establish that the treatments being used for migraine are 
not contraindicated for the coexistent disease.
C.  Establish that the treatments being used for coexistent 
conditions do not exacerbate migraine.
D. Beware of all drug interactions.
We must take into account direct special attention to women 
who are pregnant or want to become pregnant. Preventive 
medications may have teratogenic effects. If treatment is 
absolutely necessary, select a treatment with the lowest risk 
of adverse effects to the fetus.
Moreover is very important to remember that the 
topiramate in high doses favors the conception.
Many migraine patients try non pharmacologic treatment 
to manage their headaches before they begin drug therapy or 
concurrently with drug therapy. Behavioral treatments are 
classified into three broad categories: relaxation training, 
biofeedback therapy, and cognitive-behavioral training 
(stress-management training). Physical treatment includes 
acupuncture, cervical manipulation, and mobilization 
therapy. These are treatment options for headache sufferers 
who have one or more of the following characteristics:
A. Patient preference for non pharmacologic interventions
B.  Poor tolerance to specific pharmacologic treatments
C.  Medical contraindications for specific pharmacologic 
treatments
D. Insufficient or no response to pharmacologic treatment
E.  Pregnancy, planned pregnancy, or nursing
F.  History of long-term, frequent, or excessive use of 
analgesic or acute medications that can aggravate 
headache problems (or lead to decreased responsiveness 
to other pharmacotherapies)
G. Significant stress or deficient stress-coping skills.
Antiepileptic drugs (AEDs)  
in migraine, the pathophysiology  
of migraine, and AEDs25–42
Brief overview
Migraine is a disorder with a clear genetic basis. One of the 
most important aspects of the pathophysiology of migraine 
is the inherited nature of the disorder. It is clear from clinical 
practice that many patients have first-degree relatives who 
also suffer from migraine. Transmission of migraine from 
parents to children has been reported as early as the 17th 
century, and numerous published studies have reported a 
positive family history.2,5,9
The fundamental problem with migraine is in the brain, 
although the exact site of initiation, whether in the cerebral 
cortex or brainstem, is still an issue of controversy.
Cortical spreading depression (CSD) is a slowly 
propagating (2 to 6 mm/min) wave of sustained neuronal 
depolarization, which is followed by potent, relatively 
long-lasting neural suppression. The aura clinical phenomenon 
occurring in patients with MA is very related to the 
electrophysiological manifestations of CSD that were 
observed by Leao on experimental animals.43,44 So, CSD is 
considered as the electrophysiological substrate of migraine 
aura, and many consider it necessary for the development 
of headache. CSD has the property of causing inflammation 
at the peripheral vascular component and of activating the 
trigeminal nucleus caudalis.26,27
After brainstem activation and/or CSD, the trigeminal 
system (TS) is activated, releasing neuropeptides in the 
brainstem and in the peripheral nerve endings at the 
meninges. Actions of these neuropeptides at peripheral sites 
(in the meninges) and within the brain play an important role 
in the generation and maintenance of headache pain and 
possibly other migraine symptoms.
Accordingly, pain generation in migraine is a consequence 
of cortical hyper excitability and central activation in 
pain-important areas, as well as the peripheral inflammation 
that follows. The presumable mechanism of action of AEDs 
in migraine is probably due to decreasing brain excitability, as 
Table 1 Preventive therapy
When Goals
More than 3 days per month Reduce frequency
Duration  48 hours Reduce severity
Acute medications ineffective Avoid headache 
medication scalation
Contraindicated or overused
Prolonged aura or true 
migrainous infarction, 
uncommon migraine 
conditions
Reduce risk
Degree of disability improved quality of lifeTherapeutics and Clinical Risk Management 2009:5 666
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well as increasing the threshold for activation in the brainstem 
areas important for initiating migraine.
Many AEDs has been used successfully in migraine 
prophylaxis. We will focus specially on topiramate.31–42
Topiramate24,25,31–42
Topiramate is a sulfamate-substituted monosaccharide 
derived from the enantiomer of fructose. Tablets are available 
in doses of 25 mg, 100 mg, and 200 mg. In the US it is 
indicated as adjunctive therapy for partial-onset seizures and 
primary generalized tonic-clonic seizures in patients older 
than 2 years of age.
Topiramate, the most recent medication approved by 
the US Food and Drug Administration (FDA) for headache 
prevention, has proven to be an effective pharmacologic 
agent at doses ranging from 50 to 200 mg/day. Its efficacy is 
similar to that of divalproex, and it has not been shown to be 
superior to β-blockers or tricyclic antidepressants, although 
clinical experience sometimes suggests that it is.
It is absorbed rapidly from the gastrointestinal tract, has a 
long duration of action, and renal excretion is a major route of 
elimination. The elimination half-life is approximately 21 hours, 
and it is poorly bound to plasma proteins.
Topiramate has been demonstrated to modify several 
receptor-gated and voltage-sensitive ion channels, including 
voltage-activated Na+ and Ca2+ channels and non NMDA 
receptors that have been implicated in the pathophysiology 
of epilepsy and migraine. It is able to limit sustained 
repetitive firing, probably as a result of an interaction with the 
voltage-sensitive Na+ channel by reducing voltage activated 
Na+ currents. It has also been reported to modulate AMPA/
kainate receptor-mediated excitatory neurotransmission 
resulting in a decrease of fast excitatory neurotransmission and 
attenuation of focal firing. By enhancement of GABA-evoked 
currents, topiramate has been shown to increase the frequency 
of channel opening and the burst frequency without having 
an effect on the duration of either. The result of such action 
is an increase of membrane hyperpolarization, an elevated 
seizure threshold and a decrease of focal firing. In vitro studies 
have shown that the topiramate effect is not reversed by the 
benzodiazepine antagonist flumazenil, therefore suggesting 
a different binding site on the GABAA receptor or a novel 
site on the GABAA receptor complex than benzodiazepines. 
Investigations have shown topiramate to modulate both 
N- and L-type high-voltage Ca2+ channels in CA1 pyramidal 
neurons resulting in a decrease of neurotransmitter release and 
of sustained membrane depolarization. Topiramate weakly 
inhibits the carbonic anhydrase (CA) isoenzymes CA II and 
CA IV, which decreases excitatory neurotransmission, enhances 
inhibitory neurotransmission, activates a hyperpolarizing K+ 
conductance and stabilizes neuronal membranes.
Topiramate is one of the only AEDs associated with 
weight loss.37 Adverse effects include paresthesias, cognitive 
deficits, nephrolithiasis, acute closed-angle glaucoma, and 
non-anion gap metabolic acidosis (the last three are considered 
idiosyncratic in nature). One and a half percent of adults 
exposed to topiramate during its development experienced the 
occurrence of kidney stones, which is approximately 2 to 4 times 
more than the incidence that would be expected in a population 
of that size. It is thought that this association results from the 
weak carbonic anhydrase inhibition exerted by topiramate, 
which also may explain the paraesthesias.
A dosage of 50 mg twice daily has been shown to be 
optimal, but effects have been shown with dosages as low 
as 25 mg twice daily.
Topiramate has demonstrated therapeutic clinical benefits 
as a preventive treatment in episodic and chronic subtypes 
of cluster headache and was mentioned as useful in the 
management of chronic migraine, basilar migraine and 
vestibular migraine.
Benefits and cost of topiramate
Optimizing the use of prophylactic treatment may decrease 
the frequency and severity of attacks thus reducing the burden 
of disease. In this regard, topiramate has been found to be 
as effective as propranolol in the prevention of migraine 
attacks. In the present study, a cost-minimization analysis 
was performed. Monthly preventive medication cost and 
price per migraine attack reduced were used as measures. 
In comparison with propranolol and flunarizine, topiramate 
was identified as being the most costly option for migraine 
prophylaxis with a monthly drug cost of US$24.97 to 
45.04 as compared with propranolol (US$1.72 to 6.87) and 
flunarizine (US$6.09 to 12.18). Current treatment options 
would appear to offer better value for money in achieving 
effective migraine prophylaxis unless additional benefits can 
be identified for topiramate in this patient group.32,33,37
Table 2 Medication use
Use Considering
Evidence-based efficacy Topiramate among others
initiate with the lowest effective 
dose
50 mg per day for topiramate
At least 2–3 months Re-evaluate therapy
Tapering after 9–12 months Re-evaluate therapy
Avoid interfering medications Avoid ergot therapyTherapeutics and Clinical Risk Management 2009:5 667
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A previously published decision-analytic model assessing 
the clinical and economic consequences of topiramate 
versus no preventive treatment in migraineurs was updated 
with new published literature and unpublished clinical trial 
data. The model captured baseline migraine days, treatment 
discontinuation, treatment response (ie, 75%, 50% to 74%, 
and 50% reduction in migraine frequency), hours of 
disability, cost of preventive therapy, cost of acute treatment 
(pharmacy and medical service), and wages. Topiramate 
was associated with 29 fewer migraine-days and 78 fewer 
hours of disability per year, compared with no preventive 
treatment. The incremental cost per migraine-day averted for 
topiramate versus no preventive treatment was US$29 when 
only direct medical costs were considered and dollar 2 when 
total costs were included. Model results were sensitive to 
baseline migraine-days, response probability, and probability 
of an attack being treated with a triptan. Topiramate may be 
a cost-effective treatment for the prevention of migraine.
Topiramate and CM
In a recent paper Silberstein39 analyzed the biggest two 
randomized, double-blind, placebo-controlled, multicenter trials 
investigating the efficacy and safety of topiramate in the treatment 
of patients with CM, and their data suggest that topiramate at a 
dose of 100 mg daily is effective and well tolerated.
In a US trial conducted in 46 centers,40 clinical efficacy 
results included a significant reduction in mean monthly rate 
migraine/migranous days in patients receiving topiramate 
compared with placebo and a mean reduction from baseline 
migraine days per month, compared with the placebo group. 
In a European study41 topiramate significantly reduced mean 
monthly migraine days compared with placebo and also 
reduced the mean number of migraine periods and attacks at 
all time points during the double blind phase (except week 8) 
compared with placebo. The difference between both studies 
was that patients were allowed to take acute rescue medication 
as usual during the European trial. Interestingly, the benefits 
of topiramate extended to the subgroup of patients overusing 
acute medications.
Topiramate and basilar migraine (BM)
BM is the most common migraine “variant,” representing 
3% to 19% of migraine in children. BM is characterized by 
attacks of dysarthria, vertigo, tinnitus, hypacusia, diplopia, 
visual symptoms simultaneously in both temporal or nasal 
visual fields, ataxia, decreased level of consciousness, 
simultaneously bilateral paraesthesias and/or followed by 
migraine headache.
An outpatient, double-blind, parallel-group, dose comparison 
study with 2 phases: pre-randomization (screening/washout and 
4-week prospective baseline) and 12-week double blind (titration 
and maintenance), was conducted by Lewis and Paradiso42 to 
assess the efficacy and safety of topiramate for prophylaxis of 
BM in children and adolescents (6 to 18 years).
The results in 14 children (4 boys, 10 girls) who completed 
the double-blind phase (7 in the 25-mg group and 7 in the 
100-mg group) were: during the prospective baseline, the mean 
headache frequency of the combined group “all migraines” 
per month was 4.5/month (25 mg) and 4.8/month (100 mg). 
Average duration of migraine was 5.5 hours (25 mg) and 
5.0 hours (100 mg) and average mean pain (5-point faces 
scale) was 3.3 for both (25 mg 100 mg).
Overall, 86% of patients responded with a greater than 
50% reduction in migraine frequency. There were no serious 
adverse events.
Topiramate and cluster headache (CH)
CH is a well-characterized, strictly unilateral headache 
with cranial autonomic features and can be classified as 
episodic or chronic subtypes. Cluster attacks reliably are 
short-lived, often have a clockwise regularity, and can occur 
daily for weeks or months during an active cluster period. 
Pharmacologic treatment for this disorder can be divided into 
abortive and prophylactic agents. Prophylactic agents aim to 
quickly induce and maintain a remission.
Short-term prophylaxis may be attained with the use of 
steroids, ergotamine, or methysergide, but these agents are 
not as suitable for continuous use. Verapamil and lithium 
commonly are used for longer periods and other agents, such 
as melatonin and baclofen, also are considered useful. There 
have been few open label trials which proved that topiramate 
is a useful option to treat CH.45–47
Topiramate and vestibular migraine (vM)
Even when the Internation Headache Society did not include this 
form of migraine variant in this last classification1 it is universally 
accepted in neuro-otological circles.48,49 With the establishment 
of the Neuhauser criteria50 there is a tool available to evaluate 
and to measure results of the treatment in these patients.
VM can manifest as a central or peripheral vestibular syn-
drome. In our opinion these are two different types of VM. In 
the central form the crisis and/or vestibular central signs last 
many our or days,51 in the peripheral one the crisis last hours, 
usually there are unilateral auditory symptoms and a higher 
risk of sudden deafness, posed the differential diagnosis with 
Méniére’s disease.52 One important clinical feature of this Therapeutics and Clinical Risk Management 2009:5 668
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migraine variant is that the headache is present only in the third 
part of the crisis and could be previous to, simultaneous to or 
after the vertigo crisis. In an open trial we report successful 
treatment of VM patients with auditory symptoms, speculating 
that the inhibition of carbonic anhydrase could be useful in this 
subtype of VM. Central pattern forms (not peripheral) have a 
good response too along with the headache.53–55
The so-called paroxysmal vertigo of childhood and the 
paroxysmal torticollis in infancy are considered migraine 
equivalents.56,57
Motion sickness is a common association with vestibular 
migraine58,59 and there is some evidences of the genetic nature 
of the syndrome.60–62
effects on MA
There are few reports on these topics. Lampl et al studied 
12 patients with migraine with aura, in all 12 patients after 
6 months of treatment, this did not statistically influence 
aura frequency or duration compared with baseline.63 Mild 
to moderate side effects were observed, but, consistent with 
previous observations, migraine frequency as well as headache 
intensity and duration improved statistically significantly.
Doses and duration of the treatment
In the vast majority of the trials the average dose used was 
100 mg daily and the results were tested in about the first 
3 months of treatment. There is evidence that with only 50 mg 
per day (considered a low dose) the results are the same as 
in our personal experience. We recommend an average of 
9 months’ duration of treatment.53–55
Conclusions
Topiramate has an extensive evidence base provided by 
double-blind, placebo-controlled trials, which have shown 
it to be a safe, effective and well tolerated drug in the 
management of migraine.64–65 It has also been shown to have a 
role in the management of CM, VM and CH, which represent 
a challenge to primary care clinicians as well as headache 
specialists. Studies have demonstrated that topiramate can 
also be effective in preventing migraine in childhood and 
adolescence. It has been shown in models both in the US and 
the UK to offer a cost benefit when direct and indirect costs 
are evaluated by reduced work loss, improved quality of life 
and reduced use of increasingly scarce health resources.
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